IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.47 USD
-0.01 (-1.35%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $0.45 -0.02 (-3.85%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIGC Pharma, Inc. (IGC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.38 | $3.50 | $3.25 | 619.15% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for IGC Pharma, Inc. comes to $3.38. The forecasts range from a low of $3.25 to a high of $3.50. The average price target represents an increase of 619.15% from the last closing price of $0.47.
Analyst Price Targets (2 )
Broker Rating
IGC Pharma, Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on only one recommendation.
Of the two recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 50% of all recommendations. A month ago, Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 0 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Alliance Global Partners | James Molloy | Not Available | Strong Buy |
6/21/2024 | Ascendiant Capital Markets | Edward M Woo | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 2 |
Average Target Price | $3.38 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | NA |